Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Rezurock (belumosudil mesilate) — Sanofi Winthrop Industrie
EMA authorised Rezurock (belumosudil mesilate) for graft-versus-host disease with conditional approval; Orphan medicine designation.
-
EMA guidance · 2026-07-16EMA Opinion: Xervyteg (allogeneic faecal microbiota, pooled) — MaaT PHARMA
EMA opinion on Xervyteg (allogeneic faecal microbiota, pooled) for graft-versus-host disease.
-
EMA guidance · 2026-07-15EMA Opinion under re-examination: Yartemlea (narsoplimab) — Omeros Ireland Limited
EMA opinion under re-examination for Yartemlea (narsoplimab) by Omeros Ireland Limited in therapeutic areas including Thrombotic Microangiop…
-
CLINICAL_TRIALS trial_result · 2026-06-12Clinical Trial Results: Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease [Phase 1, Phase 2]
Phase 1/2 trial investigating topical fibrinogen-depleted human platelet lysate for dry eye associated with graft-versus-host disease; resul…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor [Phase 3]
Phase III study comparing ATG-thymoglobulin vs ATLG-grafalon for GVHD prophylaxis in elderly AML/MDS patients undergoing matched unrelated d…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
This update describes improved methods for selecting donor cells used in bone marrow transplant alternatives, and the trial is currently rec…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease [NA]
This clinical trial investigates whether routine dental cleaning can help prevent chronic graft-versus-host disease in patients undergoing h…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial update evaluating alpha-1 antitrypsin for the prevention of graft-versus-host disease in patients undergoing …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]
A Phase 1 clinical trial is evaluating ruxolitinib with and without abatacept (CTLA-4Ig) for prophylaxis of graft-versus-host disease and cy…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Prebiotic Galacto-oligosaccharide and Acute GVHD [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating galacto-oligosaccharide as a prebiotic for acute graft-versus-host disease is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Pediatric cGVHD Symptom Scale
A pediatric clinical trial update describes a study evaluating a symptom scale for graft-versus-host disease in children, with recruitment o…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation [Phase 1]
Phase 1 trial evaluating belimumab to prevent chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation has comp…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]
This clinical trial update reports on a Phase 1/2 study of alvelestat (MPH966), an oral neutrophil elastase inhibitor, for bronchiolitis obl…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Establishment of Biomarker Panel For Forecasting Chronic Graft-Versus-Host Disease (cGVHD) After Allo-HSCT [NA]
This document reports a clinical trial update on developing a biomarker panel to forecast chronic graft-versus-host disease following alloge…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
This ClinicalTrials.gov study is an ongoing natural history study to identify clinical and biological factors that determine outcomes in chr…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease [Phase 2]
A Phase 2 clinical trial evaluating belumosudil combined with rituximab as primary treatment for chronic graft-versus-host disease is curren…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Improving Outcomes Assessment in Chronic GVHD
This ClinicalTrials.gov entry describes a study aimed at improving outcome assessment in chronic graft-versus-host disease, with the trial c…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
This clinical trial update describes a long-term evaluation and follow-up care program for patients who received stem cell transplants.
-
EMA approval · 2026-04-17EMA Authorised: Rezurock (belumosudil mesilate) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Rezurock (belumosudil mesilate) for graft-versus-host disease under conditional approval and orphan…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease [EARLY_Phase 1]
An early Phase 1 clinical trial evaluating the addition of cord blood–derived mesenchymal stromal cells to ruxolitinib for treating steroid-…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]
Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantat…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Itacitinib for the Prevention of Graft Versus Host Disease [Phase 2]
Phase 2 clinical trial evaluating Itacitinib to prevent graft-versus-host disease after hematopoietic stem cell transplantation is active bu…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) [Phase 3]
This Phase 3 randomized trial compares tacrolimus/methotrexate/ruxolitinib versus post-transplant cyclophosphamide/tacrolimus/mycophenolate …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations [Phase 2]
This is a Phase 2 pilot study at MD Anderson evaluating whether PET/CT imaging with the tracer 18F-4FN correlates with manifestations of chr…
-
CLINICAL_TRIALS withdrawal · 2026-04-16Clinical Trial Update: hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation [Phase 1]
A Phase 1 clinical trial evaluating hAESCs to prevent acute graft-versus-host disease after hematopoietic stem cell transplantation has been…